ArticleLung2025
Synergistic Interactions Between the Quinolone-Derived Compound HT61 and Tobramycin Against a Range of Clinical Isolates of Pseudomonas aeruginosa In Vitro.
Article in Lung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial-resistant pathogens such as Pseudomonas aeruginosa (P. aeruginosa) represent a significant challenge to patients with respiratory diseases including Cystic Fibrosis (CF) and chronic obstructive pulmonary disease (COPD), where treatment of such infections is exacerbated by a shortage of new and effective antibiotic classes. One novel approach utilises 'antibiotic enhancers' that potentiate the antimicrobial activity of existing antibiotics. HT61, a small quinolone-derived compound, potentiates the activity of the aminoglycosides tobramycin and gentamicin against Staphylococcus aureus and P. aeruginosa. In this study, we have investigated synergism between tobramycin and HT61 using a panel of tobramycin-sensitive and -resistant clinical isolates of P. aeruginosa from CF patients.
methodsMicrodilution methods and chequerboard analysis were used to evaluate antimicrobial synergy of drug combinations against 63 isolates. Bacterial time-kill assays and biofilm eradication assays were then used to further characterise antimicrobial synergy against 13 selected isolates.
results74% of isolates (47/63) demonstrated evidence of either positive interactions (29/63) determined by a Fractional Inhibitory Concentration Index (FICI) ≤ 1.0, or synergy (18/63) determined by an FICI value of ≤ 0.5. Using a sub-selection of these isolates, clear augmentation of tobramycin's antimicrobial activity was observed in both time-kill assays and biofilm eradication assays regardless of FICI classification with significant reductions observed in combination therapies vs monotherapies.
conclusionsThe expansion of previous studies highlighting the potentiating capabilities of HT61 on/with antibiotics in vivo across a further 63 clinical isolates of P. aeruginosa in a laboratory setting further highlights the potential therapeutic benefits of HT61-tobramycin combinations in respiratory diseases associated with drug-resistant P. aeruginosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.